Clinical Trial

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and metastatic pancreatic cancer
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-02-16; most recent amendment 2026-04-08.
Status change: Not Yet Recruiting → Recruiting 2024-08-22
Trial Details
NCT Number NCT05257993
Lead Sponsor Onconic Therapeutics Inc.
Conditions Pancreatic Ductal Adenocarcinoma
Enrollment 71 participants
Start Date 2022-03-30
Primary Completion 2030-04 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-13